Mesalazine

CLINICAL USE

Induction and maintenance of remission in ulcerative colitis

DOSE IN NORMAL RENAL FUNCTION

Dose depends on preparation

PHARMACOKINETICS

Molecular weight :153.1

%Protein binding :40–50

%Excreted unchanged in urine : No data

Volume of distribution (L/kg) :No data

half-life – normal/ESRD (hrs) :0.6/–

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Caution – use only if necessary. Start with low dose and increase according to response

10 to 20 : Caution – use only if necessary. Start with low dose and monitor closely

<10 : Caution – use only if necessary. Start with low dose and monitor closely

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unlikely to be dialysed. Dose as in GFR <10 mL/min

HD :Unlikely to be dialysed. Dose as in GFR <10 mL/min

HDF/high flux :Unknown dialysability. Dose as in GFR <10 mL/min

CAV/VVHD :Unknown dialysability. Dose as in GFR 10 to 20 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

None known

ADMINISTRATION

Reconstition

–

Route

Oral, PR

Rate of Administration

–

Comments

–

OTHER INFORMATION

Mesalazine is excreted rapidly by the kidney, mainly as its metabolite N-acetyl-5-aminosalicylic acidNephrotoxicity has been reported Mesalazine is best avoided in patients with established renal impairment, but if necessary should be used with caution, and the patient carefully monitored

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home